Drug Patents owned by Allergan

1. List of Acular Ls drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8008338 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216167 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 3 months from now)

US8541463 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 3 months from now)

US8648107 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 3 months from now)

US8906950 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 3 months from now)

US8946281 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 3 months from now)

US8207215 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 3 months from now)

US8377982 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 3 months from now)

US8207215

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(1 year, 9 months from now)

US8541463

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(1 year, 9 months from now)

US8377982

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(1 year, 9 months from now)

US8008338

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2027

(4 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 30 May, 2003

Treatment: A method of treating ocular pain and/or enhancing ocular comfort; A method of treating or reducing ocular pain and burning/stinging; A method of treating or preventing ocular pain and burning; A method of treating ocular pain; A method of controlling postoperative ocular pain and burning/stinging in a patient; A method of treating or preventing ocular pain and burning/stinging following corneal surgery; A method of treating or preventing ocular pain in a patient

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACULAR LS before it's patent expiration?
More Information on Dosage

2. List of Acuvail drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7842714 ALLERGAN Ketorolac tromethamine compositions for treating ocular pain
Aug, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8992952 ALLERGAN Compositions for delivery of therapeutics into the eyes and methods for making and using same
Aug, 2024

(1 year, 6 months from now)

US8512717 ALLERGAN Compositions for delivery of therapeutics into the eyes and methods for making and using same
Mar, 2028

(5 years from now)

US9192571 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Mar, 2028

(5 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 22 July, 2009

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACUVAIL before it's patent expiration?
More Information on Dosage

3. List of Alphagan P drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9295641

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(1 year, 21 days ago)

US9687443

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(1 year, 21 days ago)

US6562873

(Pediatric)

ALLERGAN Compositions containing therapeutically active components having enhanced solubility
Jan, 2022

(1 year, 21 days ago)

US6627210

(Pediatric)

ALLERGAN Compositions containing α-2-adrenergic agonist components
Jan, 2022

(1 year, 13 days ago)

US6673337

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(1 year, 5 days ago)

US6641834

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(1 year, 3 days ago)

US8858961 ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Sep, 2023

(6 months from now)

US8858961

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Mar, 2024

(1 year, 30 days from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 19 August, 2005

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ALPHAGAN P before it's patent expiration?
More Information on Dosage

4. List of Avycaz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7112592 ALLERGAN Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
Jan, 2026

(2 years from now)

US8471025 ALLERGAN Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Aug, 2031

(8 years from now)

US9695122 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(9 years from now)

US8969566 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(9 years from now)

US9284314 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7612087 ALLERGAN Heterocyclic compounds as inhibitors of beta-lactamases
Nov, 2026

(3 years from now)

US8835455 ALLERGAN Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Oct, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 25, 2020
Generating Antibiotic Incentives Now (GAIN) Feb 25, 2025

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 25 February, 2015

Treatment: A method of treating bacterial infections in complicated intra-abdominal infection and complicated urinary tract infection, including pyelonephritis, patients comprising administering a bactericidally effective amount of avibactam sodium; A method of treating bacterial infections in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pnenumonia (habp/vabp) patients comprising administering a bactericidally effective amount of avibactam sodium; Method of treating bacterial infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

5. List of Byvalson drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803838 ALLERGAN Compositions comprising nebivolol
Aug, 2026

(3 years from now)

US7838552 ALLERGAN Compositions comprising nebivolol
Oct, 2027

(4 years from now)

Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient

Market Authorisation Date: 03 June, 2016

Treatment: Method of treating hypertension

Dosage: TABLET;ORAL

How can I launch a generic of BYVALSON before it's patent expiration?
More Information on Dosage

6. List of Canasa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8217083 ALLERGAN Mesalamine suppository
Jun, 2028

(5 years from now)

US8436051 ALLERGAN Mesalamine suppository
Jun, 2028

(5 years from now)

Drugs and Companies using MESALAMINE ingredient

Market Authorisation Date: 05 January, 2001

Treatment: NA

Dosage: SUPPOSITORY;RECTAL

How can I launch a generic of CANASA before it's patent expiration?
More Information on Dosage

7. List of Combigan drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7642258 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(9 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7320976 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(9 months ago)

US9474751 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(9 months ago)

US7030149 ALLERGAN Combination of brimonidine timolol for topical ophthalmic use
Apr, 2022

(9 months ago)

US9907802 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(9 months ago)

US8748425 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(9 months ago)

US8354409 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(9 months ago)

US9907801 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(9 months ago)

US9770453 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(9 months ago)

US8133890 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(9 months ago)

US7323463 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Jan, 2023

(12 days ago)

Drugs and Companies using BRIMONIDINE TARTRATE; TIMOLOL MALEATE ingredient

Market Authorisation Date: 30 October, 2007

Treatment: Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop. dose is one drop of combigan in the affected eye twice daily; Reduction of elevated intraocular pressure; Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with comparable efficacy to brimonidine 0.2% tid; Reduction of intraocular pressure in patients with elevated intraocular pressure or glaucoma; Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with a reduction in specified adverse events, compared to brimonidine 0.2% tid; Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with comparable efficacy, and a reduction in specified adverse events, compared to brimonidine 0.2% tid; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of COMBIGAN before it's patent expiration?
More Information on Dosage

8. List of Dalvance drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8143212 ALLERGAN Dalbavancin compositions for treatment of bacterial infections
Nov, 2023

(9 months from now)

US7119061 ALLERGAN Dalbavancin compositions for treatment of bacterial infections
Nov, 2023

(9 months from now)

US7115564 ALLERGAN Stable pharmaceutical compositions of dalbavancin and methods of administration
Nov, 2023

(9 months from now)

US6900175 ALLERGAN Methods of administering dalbavancin for treatment of bacterial infections
Dec, 2023

(10 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 23, 2019
New Patient Population (NPP) Jul 22, 2024
Generating Antibiotic Incentives Now (GAIN) May 23, 2024

Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient

NCE-1 date: May, 2023

Market Authorisation Date: 23 May, 2014

Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

9. List of Fetzima drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8865937 ALLERGAN Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
May, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43879 ALLERGAN Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug
Jan, 2026

(2 years from now)

US8481598 ALLERGAN Stable dosage forms of levomilnacipran
Mar, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
M Oct 7, 2022

Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient

Market Authorisation Date: 25 July, 2013

Treatment: Treatment of major depressive disorder (mdd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of FETZIMA before it's patent expiration?
More Information on Dosage

10. List of Gelnique drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10449173 ALLERGAN Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Nov, 2029

(6 years from now)

US9259388 ALLERGAN Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Nov, 2029

(6 years from now)

US8920392 ALLERGAN Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Mar, 2031

(8 years from now)

Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient

Market Authorisation Date: 27 January, 2009

Treatment: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence with a single unit dose of 10% oxybutynin chloride gel; Treatment of overactive bladder by application of oxybutynin chloride gel to skin

Dosage: GEL;TRANSDERMAL

How can I launch a generic of GELNIQUE before it's patent expiration?
More Information on Dosage

11. List of Gelnique 3% drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7198801 ALLERGAN Formulations for transdermal or transmucosal application
Jun, 2022

(7 months ago)

Drugs and Companies using OXYBUTYNIN ingredient

Market Authorisation Date: 07 December, 2011

Treatment: NA

Dosage: GEL, METERED;TRANSDERMAL

More Information on Dosage

12. List of Lastacaft drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10617695 ALLERGAN Ophthalmic compositions containing alcaftadine
Mar, 2027

(4 years from now)

US8664215 ALLERGAN Ocular allergy treatments with alcaftadine
Dec, 2027

(4 years from now)

Drugs and Companies using ALCAFTADINE ingredient

Market Authorisation Date: 28 July, 2010

Treatment: Use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of LASTACAFT before it's patent expiration?
More Information on Dosage

13. List of Latisse drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8038988 ALLERGAN Method of enhancing hair growth
Aug, 2023

(6 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8263054 ALLERGAN Method of enhancing hair growth
Jan, 2023

(16 days ago)

US8986715 ALLERGAN Method of enhancing hair growth
Jan, 2023

(16 days ago)

US9226931 ALLERGAN Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Jan, 2023

(16 days ago)

US8632760 ALLERGAN Method of enhancing hair growth
Jan, 2023

(16 days ago)

US8758733 ALLERGAN Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Jan, 2023

(16 days ago)

US9216183 ALLERGAN Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Jan, 2023

(16 days ago)

US8101161 ALLERGAN Method of enhancing hair growth
May, 2024

(1 year, 3 months from now)

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 24 December, 2008

Treatment: Method of increasing eyelash growth including length, thickness, darkness and/or number of eyelashes by administering bimatoprost to an eyelid margin; Method of increasing hair growth; Method of increasing growth of hair including eyelashes; Method of increasing eyelash growth; Method of stimulating hair growth; Treatment of hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness

Dosage: SOLUTION/DROPS;TOPICAL

How can I launch a generic of LATISSE before it's patent expiration?
More Information on Dosage

14. List of Lexapro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6916941 ALLERGAN Crystalline composition containing escitalopram
Aug, 2022

(5 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7420069 ALLERGAN Crystalline composition containing escitalopram
Aug, 2022

(5 months ago)

US7420069

(Pediatric)

ALLERGAN Crystalline composition containing escitalopram
Feb, 2023

(11 days from now)

US6916941

(Pediatric)

ALLERGAN Crystalline composition containing escitalopram
Feb, 2023

(11 days from now)

Drugs and Companies using ESCITALOPRAM OXALATE ingredient

Market Authorisation Date: 14 August, 2002

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of LEXAPRO before it's patent expiration?
More Information on Dosage

15. List of Linzess drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080526 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(11 months from now)

US7704947 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(11 months from now)

US7745409 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(11 months from now)

US7371727 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(11 months from now)

US7304036 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Aug, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8110553 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(11 months from now)

US8933030 ALLERGAN Treatments for gastrointestinal disorders
Feb, 2031

(8 years from now)

US10702576 ALLERGAN Stable formulations of linaclotide
Aug, 2031

(8 years from now)

US10675325 ALLERGAN Stable formulations of linaclotide
Aug, 2031

(8 years from now)

US8802628 ALLERGAN Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration
Oct, 2031

(8 years from now)

US8748573 ALLERGAN Formulations comprising linaclotide
Oct, 2031

(8 years from now)

US9708371 ALLERGAN Treatments for gastrointestinal disorders
Aug, 2033

(10 years from now)

Drugs and Companies using LINACLOTIDE ingredient

Market Authorisation Date: 30 August, 2012

Treatment: Method of treating irritable bowel syndrome with constipation in adults; Method of treating chronic idiopathic constipation in adult patients.; Method of treating irritable bowel syndrome with constipation in adult patients.

Dosage: CAPSULE;ORAL

How can I launch a generic of LINZESS before it's patent expiration?
More Information on Dosage

16. List of Lumigan drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7851504 ALLERGAN Enhanced bimatoprost ophthalmic solution
Jun, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9241918 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

US8309605 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

US8586630 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

US8524777 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

US9155716 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

US8338479 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

US8772338 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

US8299118 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

US8933120 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

US8933127 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

US8278353 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 31 August, 2010

Treatment: Method of treating glaucoma or elevated intraocular pressure; A method of lowering intraocular pressure in a patient with open angle glaucoma or ocular hypertension; Method of treating glaucoma in a patient; A method of reducing intraocular pressure in patients with open angle glaucoma or ocular hypertension; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension; A method of lowering intraocular pressure; A method of treating a patient with glaucoma or ocular hypertension

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of LUMIGAN before it's patent expiration?
More Information on Dosage

17. List of Namenda Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8039009 ALLERGAN Modified release formulations of memantine oral dosage forms
Mar, 2029

(6 years from now)

US8039009

(Pediatric)

ALLERGAN Modified release formulations of memantine oral dosage forms
Sep, 2029

(6 years from now)

Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 June, 2010

Treatment: Treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of NAMENDA XR before it's patent expiration?
More Information on Dosage

18. List of Namzaric drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338485 ALLERGAN Compositions for the treatment of CNS-related conditions
Nov, 2025

(2 years from now)

US8598233 ALLERGAN Method for administering an NMDA receptor antagonist to a subject
Nov, 2025

(2 years from now)

US8168209 ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(2 years from now)

US8293794 ALLERGAN Methods and compositions for the treatment of CNS-related conditions
Nov, 2025

(2 years from now)

US8173708 ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(2 years from now)

US8362085 ALLERGAN Method for administering an NMDA receptor antagonist to a subject
Nov, 2025

(2 years from now)

US8338486 ALLERGAN Methods for the treatment of CNS-related conditions
Nov, 2025

(2 years from now)

US8283379 ALLERGAN Methods and compositions for the treatment of CNS-related conditions
Nov, 2025

(2 years from now)

US8580858 ALLERGAN Compositions for the treatment of CNS-related conditions
Nov, 2025

(2 years from now)

US8329752 ALLERGAN Composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(2 years from now)

US8598233

(Pediatric)

ALLERGAN Method for administering an NMDA receptor antagonist to a subject
May, 2026

(3 years from now)

US8329752

(Pediatric)

ALLERGAN Composition for administering an NMDA receptor antagonist to a subject
May, 2026

(3 years from now)

US8283379

(Pediatric)

ALLERGAN Methods and compositions for the treatment of CNS-related conditions
May, 2026

(3 years from now)

US8168209

(Pediatric)

ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject
May, 2026

(3 years from now)

US8173708

(Pediatric)

ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject
May, 2026

(3 years from now)

US8362085

(Pediatric)

ALLERGAN Method for administering an NMDA receptor antagonist to a subject
May, 2026

(3 years from now)

US8039009 ALLERGAN Modified release formulations of memantine oral dosage forms
Mar, 2029

(6 years from now)

US8039009

(Pediatric)

ALLERGAN Modified release formulations of memantine oral dosage forms
Sep, 2029

(6 years from now)

US8058291 ALLERGAN Methods and compositions for the treatment of CNS-related conditions
Dec, 2029

(6 years from now)

Drugs and Companies using DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 December, 2014

Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of NAMZARIC before it's patent expiration?
More Information on Dosage

19. List of Ozurdex drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9192511 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(22 days ago)

US10702539 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(22 days ago)

US8506987 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(22 days ago)

US8034366 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(22 days ago)

US10076526 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(22 days ago)

US8034370 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(22 days ago)

US6899717 ALLERGAN Methods and apparatus for delivery of ocular implants
Nov, 2023

(8 months from now)

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 17 June, 2009

Treatment: Treatment of diabetic macular edema; Treatment of macular edema following branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo); Treatment of non-infectious uveitis affecting the posterior segment of the eye; Treatment of macular edema; Treatment of uveitis; Delivering an ocular implant as described in the dosage and administration section of the approved labeling of ozurdex

Dosage: IMPLANT;INTRAVITREAL

More Information on Dosage

20. List of Restasis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629111 ALLERGAN Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(1 year, 6 months from now)

US9248191 ALLERGAN Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(1 year, 6 months from now)

US8648048 ALLERGAN Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(1 year, 6 months from now)

US8633162 ALLERGAN Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(1 year, 6 months from now)

US8642556 ALLERGAN Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(1 year, 6 months from now)

US8685930 ALLERGAN Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(1 year, 6 months from now)

US8292129 ALLERGAN Dispensing device
Feb, 2031

(8 years from now)

US8561859 ALLERGAN Dispensing device
Apr, 2032

(9 years from now)

US9676525 ALLERGAN Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids
Feb, 2034

(11 years from now)

US9669974 ALLERGAN Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids
May, 2034

(11 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 23 December, 2002

Treatment: Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).; Increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dosage: EMULSION;OPHTHALMIC

How can I launch a generic of RESTASIS before it's patent expiration?
More Information on Dosage

21. List of Saphris drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8022228 ALLERGAN Crystal form of asenapine maleate
Apr, 2026

(3 years from now)

US7741358 ALLERGAN Crystal form of asenapine maleate
Apr, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7741358

(Pediatric)

ALLERGAN Crystal form of asenapine maleate
Oct, 2026

(3 years from now)

US8022228

(Pediatric)

ALLERGAN Crystal form of asenapine maleate
Oct, 2026

(3 years from now)

Drugs and Companies using ASENAPINE MALEATE ingredient

Market Authorisation Date: 13 August, 2009

Treatment: Use of the atypical antipsychotic asenapine for treatment of schizophrenia in adults; Treatment of bipolar disorder and schizophrenia; Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: as adjunctive treatment to lithium or valproate in adults; Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: acute monotherapy of manic or mixed episodes in pediatric patients age 10-17; Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: acute monotherapy of manic or mixed episodes (ages 10 to adult); Method of treating manic or mixed episodes associated with bipolar disorder in pediatric patients; Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: maintenance monotherapy in adults

Dosage: TABLET;SUBLINGUAL

How can I launch a generic of SAPHRIS before it's patent expiration?
More Information on Dosage

22. List of Savella drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6602911 ALLERGAN Methods of treating fibromyalgia
Jan, 2023

(17 days ago)

US7994220 ALLERGAN Milnacipran for the long-term treatment of fibromyalgia syndrome
Sep, 2029

(6 years from now)

Drugs and Companies using MILNACIPRAN HYDROCHLORIDE ingredient

Market Authorisation Date: 14 January, 2009

Treatment: Management of fibromyalgia (fm); Management of fibromyalgia

Dosage: TABLET;ORAL

How can I launch a generic of SAVELLA before it's patent expiration?
More Information on Dosage

23. List of Teflaro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6417175 ALLERGAN Phosphonocephem derivatives, process for the preparation of the same, and use thereof
Apr, 2022

(9 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9629861 ALLERGAN Compositions and methods for treating bacterial infections using ceftaroline
Sep, 2030

(7 years from now)

US8247400 ALLERGAN Cephem compounds useful for the treatment of bacterial infections
Feb, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Sep 13, 2022

Drugs and Companies using CEFTAROLINE FOSAMIL ingredient

Market Authorisation Date: 29 October, 2010

Treatment: Method of treating bacterial infections; Methods for treating bacterial infections

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of TEFLARO before it's patent expiration?
More Information on Dosage

24. List of Ubrelvy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8912210 ALLERGAN Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(8 years from now)

US9499545 ALLERGAN Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(8 years from now)

US8754096 ALLERGAN Piperidinone carboxamide azaindane CGRP receptor antagonists
Jul, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9833448 ALLERGAN Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(8 years from now)

US10117836 ALLERGAN Tablet formulation for CGRP active compounds
Jan, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 23, 2024

Drugs and Companies using UBROGEPANT ingredient

NCE-1 date: December, 2023

Market Authorisation Date: 23 December, 2019

Treatment: Acute treatment of migraine with or without aura in adults; Acute treatment of migraine with headache, with or without aura in adults

Dosage: TABLET;ORAL

More Information on Dosage

25. List of Viibryd drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7834020 ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Jun, 2022

(7 months ago)

US8673921 ALLERGAN Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Jun, 2022

(7 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8236804 ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
Jun, 2022

(7 months ago)

US8193195 ALLERGAN Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Jun, 2022

(7 months ago)

US8673921

(Pediatric)

ALLERGAN Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Dec, 2022

(a month ago)

US8193195

(Pediatric)

ALLERGAN Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Dec, 2022

(a month ago)

US7834020

(Pediatric)

ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Dec, 2022

(a month ago)

US8236804

(Pediatric)

ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
Dec, 2022

(a month ago)

Exclusivity Exclusivity Expiration
M Jan 31, 2023
Pediatric Exclusivity (PED) Jul 31, 2023

Drugs and Companies using VILAZODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 January, 2011

Treatment: Treatment of major depressive disorder (mdd)

Dosage: TABLET;ORAL

How can I launch a generic of VIIBRYD before it's patent expiration?
More Information on Dosage

26. List of Vraylar drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943621 ALLERGAN Salts of piperazine compounds as D3/D2 antagonists
Dec, 2028

(5 years from now)

US7737142 ALLERGAN (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
Sep, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47350 ALLERGAN Pharmaceutical formulations containing dopamine receptor ligands
Jul, 2029

(6 years from now)

USRE49110 ALLERGAN Pharmaceutical formulations containing dopamine receptor ligands
Jul, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) May 24, 2022

Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 September, 2015

Treatment: Treatment of schizophrenia and/or acute manic or mixed episodes associated with bipolar i disorder with cariprazine; Treatment of schizophrenia with cariprazine; Treatment of acute manic or mixed episodes associated with bipolar i disorder with cariprazine; Treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine

Dosage: CAPSULE;ORAL

How can I launch a generic of VRAYLAR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in